Peringatan Keamanan

LD50 (mouse, intraperitoneal) 225 mg/kg, LD50 (mouse, oral) 550 mg/kg. Symptoms of overdose include headache, drowsiness, visual disturbances, vomiting, hypokalaemia, cardiovascular collapse and cardiac and respiratory arrest. Hypotension, if not treated, may progress rapidly to shock. Electrocardiograms (ECG) may reveal atrial standstill, nodal rhythm, prolonged intraventricular conduction time, broadening of the QRS complex, and progressive bradycardia leading to ventricular fibrillation and/or arrest.

Amodiaquine

DB00613

small molecule approved investigational

Deskripsi

A 4-aminoquinoquinoline compound with anti-inflammatory properties.

Struktur Molekul 2D

Berat 355.861
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 5.2 ± 1.7 (range 0.4 to 5.5) minutes
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Rapidly absorbed following oral administration.

Metabolisme

Hepatic biotransformation to desethylamodiaquine (the principal biologically active metabolite) is the predominant route of amodiaquine clearance with such a considerable first pass effect that very little orally administered amodiaquine escapes untransformed into the systemic circulation.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

751 Data
Artemether The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Artemether.
Lumefantrine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Lumefantrine.
Mefloquine The risk or severity of adverse effects can be increased when Amodiaquine is combined with Mefloquine.
Mifepristone The serum concentration of Amodiaquine can be increased when it is combined with Mifepristone.
Atomoxetine The metabolism of Atomoxetine can be decreased when combined with Amodiaquine.
Zidovudine Zidovudine may increase the neutropenic activities of Amodiaquine.
Efavirenz Efavirenz may increase the hepatotoxic activities of Amodiaquine.
Thiethylperazine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Thiethylperazine.
Promazine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Promazine.
Prochlorperazine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Prochlorperazine.
Chlorpromazine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Chlorpromazine.
Triflupromazine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Triflupromazine.
Fluphenazine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Fluphenazine.
Thioridazine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Thioridazine.
Moricizine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Moricizine.
Trifluoperazine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Trifluoperazine.
Perphenazine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Perphenazine.
Mesoridazine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Mesoridazine.
Acetophenazine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Acetophenazine.
Promethazine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Promethazine.
Alimemazine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Alimemazine.
Methotrimeprazine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Methotrimeprazine.
Periciazine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Periciazine.
Acepromazine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Acepromazine.
Aceprometazine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Aceprometazine.
Pipotiazine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Pipotiazine.
Thioproperazine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Thioproperazine.
BL-1020 The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with BL-1020.
Cyamemazine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Cyamemazine.
Methylene blue The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Methylene blue.
Propiopromazine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Propiopromazine.
Perazine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Perazine.
Butaperazine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Butaperazine.
Chlorproethazine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Chlorproethazine.
Thiazinam The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Thiazinam.
Dixyrazine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Dixyrazine.
Perphenazine enanthate The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Perphenazine enanthate.
Dapsone The risk or severity of adverse effects can be increased when Amodiaquine is combined with Dapsone.
Acetyldigitoxin The serum concentration of Acetyldigitoxin can be increased when it is combined with Amodiaquine.
Deslanoside The serum concentration of Deslanoside can be increased when it is combined with Amodiaquine.
Ouabain The serum concentration of Ouabain can be increased when it is combined with Amodiaquine.
Oleandrin The serum concentration of Oleandrin can be increased when it is combined with Amodiaquine.
Cymarin The serum concentration of Cymarin can be increased when it is combined with Amodiaquine.
Proscillaridin The serum concentration of Proscillaridin can be increased when it is combined with Amodiaquine.
Lanatoside C The serum concentration of Lanatoside C can be increased when it is combined with Amodiaquine.
Gitoformate The serum concentration of Gitoformate can be increased when it is combined with Amodiaquine.
Peruvoside The serum concentration of Peruvoside can be increased when it is combined with Amodiaquine.
Metildigoxin The serum concentration of Metildigoxin can be increased when it is combined with Amodiaquine.
Leuprolide The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Leuprolide.
Goserelin The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Goserelin.
Azithromycin The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Azithromycin.
Moxifloxacin The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Moxifloxacin.
Sulfisoxazole The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Sulfisoxazole.
Methadone The metabolism of Methadone can be decreased when combined with Amodiaquine.
Sulpiride The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Sulpiride.
Nimodipine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Nimodipine.
Droperidol The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Droperidol.
Oxaliplatin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Amodiaquine.
Perflutren The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Perflutren.
Cinnarizine The metabolism of Cinnarizine can be decreased when combined with Amodiaquine.
Atropine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Atropine.
Adenosine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Adenosine.
Pentamidine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Pentamidine.
Gadobenic acid The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Gadobenic acid.
Carbinoxamine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Carbinoxamine.
Dolasetron The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Dolasetron.
Roxithromycin The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Roxithromycin.
Nalidixic acid The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Nalidixic acid.
Cinoxacin The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Cinoxacin.
Granisetron The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Granisetron.
Levosimendan The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Levosimendan.
Desloratadine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Desloratadine.
Telithromycin The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Telithromycin.
Lomefloxacin The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Lomefloxacin.
Dimenhydrinate The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Dimenhydrinate.
Primaquine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Primaquine.
Papaverine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Papaverine.
Chlorpheniramine The therapeutic efficacy of Amodiaquine can be increased when used in combination with Chlorpheniramine.
Gemifloxacin The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Gemifloxacin.
Ofloxacin The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Ofloxacin.
Levacetylmethadol The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Levacetylmethadol.
Mibefradil The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Mibefradil.
Probucol The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Probucol.
Terlipressin The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Terlipressin.
Prenylamine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Prenylamine.
Fluspirilene The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Fluspirilene.
Lofexidine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Lofexidine.
Azimilide The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Azimilide.
Pracinostat The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Pracinostat.
Technetium Tc-99m ciprofloxacin The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Technetium Tc-99m ciprofloxacin.
Garenoxacin The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Garenoxacin.
Tedisamil The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Tedisamil.
Tucidinostat The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Tucidinostat.
Telavancin The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Telavancin.
Nemonoxacin The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Nemonoxacin.
Nilvadipine The metabolism of Amodiaquine can be decreased when combined with Nilvadipine.
Antazoline The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Antazoline.
Bedaquiline The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Bedaquiline.
Fendiline The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Fendiline.
Eperisone The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Eperisone.

Target Protein

Fe(II)-protoporphyrin IX
Histamine N-methyltransferase HNMT

Referensi & Sumber

Synthesis reference: Burckhalter, J.H., Jones, E.M., Rawlins, A.L., Tendick, F.H, and 2,474,821; July 5,1949; assigned to Parke, Davis & Co.
Artikel (PubMed)
  • PMID: 7618347
    Jewell H, Maggs JL, Harrison AC, O'Neill PM, Ruscoe JE, Park BK: Role of hepatic metabolism in the bioactivation and detoxication of amodiaquine. Xenobiotica. 1995 Feb;25(2):199-217.
  • PMID: 1567466
    Harrison AC, Kitteringham NR, Clarke JB, Park BK: The mechanism of bioactivation and antigen formation of amodiaquine in the rat. Biochem Pharmacol. 1992 Apr 1;43(7):1421-30.

Contoh Produk & Brand

Produk: 0 • International brands: 3
International Brands
  • Basoquin
  • Camoquin — Parke Davis
  • Flavoquine

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul